Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 6/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255589 | 0.81 | KDM4E (0.59) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4250094 | 0.81 | DYRK1A (0.48) | NPC1RAB9ASMN1; SMN2ADORA1 | |
| SCHEMBL8277824 | 0.78 | NPC1 (0.71) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4246631 | 0.72 | CNR1 (0.54) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4250864 | 0.71 | PDPK1 (0.38) | KMT2ASMN1; SMN2MEN1ALDH1A1TDP1 | |
| SCHEMBL4961093 | 0.70 | KMT2A (0.67) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5713545 | 0.70 | MAPT (0.67) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL3053529 | 0.70 | NPC1 (1.00) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL4638534 | 0.70 | — | — | |
| SCHEMBL16562119 | 0.69 | NPC1 (0.80) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | claimed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | claimed |
| US-20090170914-A1 | Cermide Kinase Modulation | BORNANCIN FREDERIC | 2009-07-02 | — | — | US | disclosed |
| EP-2004617-A2 | CERAMIDE KINASE MODULATION | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007112914-A2 | CERAMIDE KINASE MODULATION | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170914-A1 | Cermide Kinase Modulation | CERS2, CHKB, SPHK2 | NPC1 247/4885RAB9A 566/4885KMT2A 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.